Premium
Effect of Curcumin on the Production of Interleukin‐6 from MDA‐MB‐231 Breast Cancer Cells
Author(s) -
Paciotti James,
CondoriSalas Ramiro,
RojasHumpire Ricardo,
PinoFigueroa Alejandro
Publication year - 2015
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.29.1_supplement.lb534
Subject(s) - curcumin , cytokine , cancer cell , cancer , breast cancer , viability assay , interleukin , cancer research , chemistry , pharmacology , immunology , medicine , cell , biochemistry
Cytokines such as interleukin‐6 (IL‐6) have an important role in cellular proliferation and survival. Overexpression of IL‐6 in inflammatory or degenerative diseases has been observed in patients with various types of cancer, arthritis and in the elderly; furthermore, it can be used as a marker of disease and degeneration. Natural agents such as Curcumin or its derivatives could produce their protective effects by inhibiting the production of IL‐6. The purpose of the current study was to investigate the inhibitory effects of Curcumin and Curcumin Diethylsuccinate on the production of IL‐6 at concentrations from 1 to 10µM in MDA‐MB‐231 breast cancer cells. Cells were cultured for 3‐5 days with Dulbecco's Modified Eagle Medium (DMEM) at 37°C and 5% CO2. Media samples were used to determine the levels of IL‐6 by enzyme‐linked immunosorbant assay (ELISA) that uses antibodies to achieve a sensitive colorimetric detection at 450 nm. IL‐6 measurements were normalized to cell viability determined by MTS assay at 490 nm. Administration of Curcumin Diethylsuccinate 1µM to MDA‐MB‐231 cells reduced their production of IL‐6 from 79±5 to 30±1 pg/mL (62%), showing that this agent has an inhibitory effect on the cytokine release from cancer cells and could be useful in the treatment of cancer and other degenerative disorders.